Colorectal cancer, a leading cause of cancer-related morbidity and mortality worldwide, has long presented therapeutic challenges due to the suppressive tumor microenvironment that dampens immune responses. Traditional vaccines targeting cancer antigens often falter as tumor-associated macrophages (TAMs) tend to adopt a phenotype that supports tumor progression rather than elimination. The new study, led by Hamdan, Gandolfi, and D’Alessio, strategically targets this hurdle by inducing “trained immunity” in macrophages, essentially reprogramming them to adopt a tumoricidal phenotype that synergizes with vaccine efforts.

Trained immunity refers to a form of long-term activation of innate immune cells characterized by epigenetic reconfigurations and metabolic shifts that enhance the cells’ responsiveness to subsequent challenges. Unlike adaptive immunity, which relies on antigen-specific memory, trained immunity represents a non-specific and durable heightened state of readiness primarily orchestrated by innate immune cells such as macrophages and natural killer cells. This fundamental shift in understanding innate immune memory has sparked a revolution in immunology, pointing to new therapeutic paradigms.

The researchers exploited beta-glucans, naturally occurring polysaccharides found in the cell walls of fungi and certain bacteria, as potent inducers of trained immunity. Beta-glucans engage receptors like Dectin-1 on macrophages, triggering downstream signals that culminate in both epigenetic modifications — such as histone methylation and acetylation — and metabolic reprogramming, including enhanced glycolysis and mitochondrial respiration. These molecular events recalibrate macrophage function from a pro-tumoral to an anti-tumoral disposition.

Detailed mechanistic investigations revealed that glucan-primed macrophages undergo a coordinated network of gene expression changes, driven by key transcription factors and chromatin remodeling complexes. This epigenetic rewiring stabilizes a phenotype that produces pro-inflammatory cytokines and reactive oxygen species, simultaneously improving antigen presentation and cytotoxic activity. Concurrently, metabolic shifts toward aerobic glycolysis furnish the energetic and biosynthetic demands to sustain this activated state, emphasizing the intertwined nature of metabolism and epigenetics in trained immunity.

Crucially, when these metabolically and epigenetically trained macrophages were introduced into preclinical models of colorectal cancer, they significantly potentiated the therapeutic benefit of cancer vaccines targeting tumor-associated neoantigens. The trained macrophages not only improved the infiltration and activation of tumor-specific T cells but also modulated the tumor microenvironment, reducing immunosuppressive factors and enhancing the overall immune surveillance. This combinatorial approach led to delayed tumor progression and improved survival outcomes in experimental studies.

The implications of this research are expansive. By reframing macrophages from passive bystanders or tumor accomplices to empowered effectors, the study provides a blueprint for next-generation immunotherapies. Leveraging trained immunity bypasses some limitations of checkpoint inhibitors and adoptive cell therapies, offering a potentially safer and more broadly applicable modality. The biomolecular insights into epigenetic and metabolic pathways also open avenues for developing novel adjuvants or small molecules that mimic glucan’s effects.

Furthermore, the study illuminates the plasticity of macrophages within the tumor milieu, challenging prior paradigms that considered TAMs irreversibly skewed. The reversible nature of epigenetic and metabolic states underscores the therapeutic window available to re-educate macrophages in situ. This dynamic reprogramming can be exploited not only for enhancing vaccines but also for synergistic approaches with chemotherapy, radiotherapy, and other immunomodulators.

Addressing translational potential, the researchers also evaluated safety and dose-response parameters in preclinical models, observing minimal systemic toxicity, which is a significant step toward clinical applicability. The use of naturally derived beta-glucans provides an additional advantage in terms of biocompatibility and cost-effectiveness, paving the way for scalable manufacturing and distribution in clinical settings.

The study also outlines challenges ahead, such as understanding long-term effects of trained immunity induction to avoid potential inflammatory or autoimmune sequelae. The heterogeneity of patient tumors and immune landscapes poses a further hurdle that will require personalized approaches or combinatorial strategies to maximize efficacy. Nevertheless, this research marks a critical milestone in unraveling the complexity of immune-tumor interactions.

In the broader context of cancer immunotherapy, these findings reinforce the paradigm shift towards harnessing innate immunity alongside adaptive responses. The integration of epigenetic and metabolic modulation into immunotherapy design exemplifies the cutting-edge of precision medicine and systems immunology. Future research trajectories include exploring analogous trained immunity induction in other innate cell populations, optimizing vaccine formulations for enhanced synergy, and clinical trials that will test these findings in human patients.

This seminal work by Hamdan and colleagues epitomizes the translational potential of fundamental immunology discoveries. By bridging molecular mechanisms with therapeutic innovation, their study lays a foundation for novel cancer treatments that re-engineer the immune system’s first line of defense into a potent weapon against colorectal cancer. The impact of such approaches could herald a new era where durable, effective immunotherapies become accessible for a disease that has long eluded curative interventions.

In conclusion, the strategic induction of trained immunity through glucan-mediated epigenetic and metabolic reprogramming of macrophages represents a paradigm-shifting approach in oncology. By fundamentally altering the immune landscape within tumors, this approach enhances vaccine efficacy and offers significant hope for improved patient outcomes. As the field advances, the convergence of innate immune training, vaccine science, and epigenetic therapeutics will likely center stage in the fight against cancer, unlocking new frontiers in personalized and durable immunotherapy.

Subject of Research:
The study focuses on leveraging glucan-induced trained immunity to epigenetically and metabolically rewire macrophages, aiming to enhance the response to colorectal cancer vaccines.

Article Title:
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.

Article References:
Hamdan, F., Gandolfi, S., D’Alessio, F. et al. Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68466-5

Image Credits: AI Generated

At the heart of this research lies IMA203, a newly developed cell therapy designed to target the PRAME peptide. PRAME is a protein abundantly expressed in a wide spectrum of tumors including melanoma, ovarian cancer, sarcomas, and lung cancer, but is minimally or not at all produced by normal, healthy cells. This selective expression of PRAME provides an ideal target, enabling engineered T cells to precisely identify and eradicate cancer cells without causing collateral damage to the patient’s normal tissues—a longstanding challenge in solid tumor oncology.

The clinical trial enrolled 40 patients who had exhausted standard treatment options. These patients had aggressive and advanced tumor diseases, many of which had shown little to no response to previous therapies. Thanks to the incorporation of a high-affinity TCR that recognizes the PRAME peptide presented on tumor cells, the T cells were reprogrammed to seek and destroy tumor cells selectively. This precision targeting marks a significant departure from earlier, less specific immunotherapies which often caused severe systemic side effects.

Results from the study were encouraging: approximately half of the treated patients, who had previously failed standard treatments, demonstrated a meaningful clinical response to IMA203 therapy. Importantly, many responses were durable, lasting not merely months but extending beyond eight months, with some patients still without relapse for over two years. This longevity of response marks a profound improvement compared to traditional chemotherapy options, which generally offer only limited durable benefit lasting a few months at best.

Equally noteworthy, the cell therapy exhibited a favorable safety profile. Patients mainly experienced manageable side effects such as mild to moderate fever and skin rashes, which were transient and resolved without serious complications. The absence of severe immune-related adverse events underscores the specificity and controlled activity of the engineered TCR T cells, a critical factor for broad clinical application in solid tumors.

Professor Martin Wermke, the head of the Early Clinical Trial Unit and the lead author of the study, heralded these findings as a transformative milestone. He emphasized that for the first time, a lasting therapeutic response has been achieved in common solid tumors through engineered T cells. Contrasting this breakthrough with current treatments, Prof. Wermke underscored not only the increased response rates but also the prolonged duration of remission, describing some cases as potentially curative, which holds tremendous promise for patients with historically poor prognoses.

Dresden University Hospital has long been a pioneer in cell therapies, particularly for hematologic malignancies. Professor Martin Bornhäuser, Director of Medical Clinic I and NCT/UCC Dresden, reflected on the historical evolution of the cell therapy program initiated over two decades ago. What was initially tailored toward blood cancers now provides vital infrastructure and expertise necessary to extend cutting-edge cell therapies like IMA203 to patients battling solid tumors, a frontier previously fraught with challenges.

Looking forward, the researchers plan to expand clinical investigations of IMA203 into larger phase 2 and 3 trials, especially focusing on melanoma patients who have failed to respond to conventional immunotherapies and targeted treatments. These upcoming studies aim to validate and potentially establish IMA203 as a new standard therapy for solid tumors, addressing an unmet medical need that affects millions worldwide. The efforts are part of a broader strategic commitment by the NCT/UCC Dresden to develop and test novel cell-based immunotherapies against a variety of challenging cancers.

The project has garnered enthusiastic support from academic leadership. Professor Esther Troost, Dean of TU Dresden’s Faculty of Medicine, lauded the perseverance and dedication of the research team, recognizing the growing prominence of oncology research at the institution. The clinical successes realized through IMA203 serve as compelling evidence that intensive investment in cellular immunotherapies can translate into tangible hope for cancer patients facing limited treatment options.

Moreover, the hospital’s Medical Director, Professor Uwe Platzbecker, highlighted that regulatory approvals for similar cell therapies targeting solid tumors are anticipated imminently. Preparations are underway to ensure that these innovative treatments can be rapidly integrated into clinical practice, maximizing patient access. This proactive stance underscores the hospital’s vision of becoming a leading center for personalized cancer immunotherapy.

Technically, the mechanism of action of IMA203 involves the genetic engineering of patient-derived T cells to express a TCR with high affinity for a PRAME peptide presented in the context of HLA molecules on tumor cell surfaces. Upon infusion back into the patient, these TCR-engineered T cells circulate and home toward tumor sites, where they recognize peptide-HLA complexes and initiate targeted cytotoxicity. This approach combines the specificity of the adaptive immune system with advances in gene editing and cell manufacturing, creating a powerful anti-tumor modality distinct from previous antibody-based or general immune-stimulating methods.

Equally critical to this therapeutic success is the manufacturing infrastructure, which ensures the production of high-quality, standardized TCR-T cell products suitable for patient administration. Dresden University Hospital’s established facilities and expertise in cell processing have enabled seamless translation of this academic innovation into a viable clinical treatment. The sustained collaboration between immunologists, oncologists, genetic engineers, and clinical trial experts has been pivotal in overcoming technical, logistical, and regulatory hurdles.

In summary, the advent of IMA203 represents a paradigm shift in the treatment of solid tumors, demonstrating that TCR-engineered T cell therapies can achieve meaningful and lasting responses with manageable toxicity profiles. As the field of cellular immunotherapy continues to evolve, these findings provide a beacon of hope that could transform cancer care, offering patients durable remissions and the possibility of long-term survival or even cures. The results reported from Dresden University Hospital are a significant step toward realizing the full potential of personalized, immune-based cancer therapies.

Subject of Research: People

Article Title: Research success at Dresden University Hospital: New cell therapy shows promising results in advanced tumor diseases

News Publication Date: 25-Apr-2025

Web References:
DOI 10.1038/s41591-025-03650-6

Image Credits: UKD/Thomas Albrecht

Keywords: T cell receptor-engineered T cells, IMA203, PRAME peptide, solid tumors, immunotherapy, melanoma, cell therapy, clinical trial, Dresden University Hospital, personalized cancer treatment, durable response, cancer immunotherapy